Stifel Nicolaus initiated coverage on shares of RAPT Therapeutics (NASDAQ:RAPT – Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $40.00 price target on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 66.32% from the stock’s previous close.
A number of other analysts have also recently commented on the stock. HC Wainwright lowered their price objective on shares of RAPT Therapeutics from $43.00 to $41.00 in a research report on Friday, May 12th. Barclays started coverage on shares of RAPT Therapeutics in a research report on Thursday, June 15th. They issued an “overweight” rating and a $35.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $40.55.
Check Out Our Latest Analysis on RAPT
RAPT Therapeutics Stock Performance
RAPT Therapeutics (NASDAQ:RAPT – Get Free Report) last released its quarterly earnings data on Thursday, May 11th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.12). As a group, research analysts forecast that RAPT Therapeutics will post -3.18 EPS for the current fiscal year.
Hedge Funds Weigh In On RAPT Therapeutics
Large investors have recently modified their holdings of the business. New England Capital Financial Advisors LLC acquired a new position in shares of RAPT Therapeutics during the 4th quarter worth about $28,000. Braidwell LP acquired a new position in shares of RAPT Therapeutics during the 4th quarter worth about $19,800,000. Kingdon Capital Management L.L.C. boosted its stake in shares of RAPT Therapeutics by 30.3% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 880,000 shares of the company’s stock worth $17,424,000 after buying an additional 204,383 shares during the last quarter. Federated Hermes Inc. acquired a new position in shares of RAPT Therapeutics during the 1st quarter worth about $321,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of RAPT Therapeutics by 40.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,688 shares of the company’s stock worth $306,000 after buying an additional 4,843 shares during the last quarter. 97.38% of the stock is currently owned by institutional investors and hedge funds.
RAPT Therapeutics Company Profile
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Featured Stories
- Five stocks we like better than RAPT Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- 3 Best Renewable Energy Stocks as Summer Heat Builds
- How to Choose Top Rated Stocks
- Kinder Morgan Shines With Dividend Yield, Cash Flow, Buybacks
- What Makes a Stock a Good Dividend Stock?
- 3 Stocks to Buy No Matter Which Way Inflation Moves
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
